Actively Recruiting
ROSY-F Ongoing Benralizumab Treatment for Participants Completing Prior Studies with Continued Clinical Benefit
Led by AstraZeneca · Updated on 2026-10-27
230
Participants Needed
47
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research focuses on participants who have completed or exited previous clinical studies involving benralizumab Fasenra and are still judged by their doctors to benefit from continued treatment. The study aims to provide continuous access to benralizumab while monitoring its long-term safety and tolerability in conditions such as asthma, eosinophilic granulomatosis with polyangiitis EGPA, and hypereosinophilic syndrome HES. It is an open-label, international, non-randomized study designed to support ongoing treatment beyond initial trials. Participants will receive benralizumab through subcutaneous injections at the same frequency as in their prior parent study. This roll-over study allows those who benefit clinically and lack access to commercial benralizumab to continue treatment under medical supervision. The study is planned to run from July 2026 through December 2029, providing ongoing treatment and monitoring. Throughout the study, participants will attend visits at the investigator site for treatment administration and safety assessments. Researchers will monitor and assess serious and non-serious adverse events from baseline until eight weeks after the last benralizumab dose. The study tracks the long-term safety and tolerability of benralizumab, ensuring participants continue to receive care and monitoring during the treatment period.
CONDITIONS
Brief Title
Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment
Research Team
A
AstraZeneca Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here